2016 Hematological Malignancies

HD7: Long-term Outcome

PFS

OS

15-year estimate [95%-CI] Arm A:

15-year estimate [95%-CI] Arm A:

52.2% [44.9% to 59.5%]

71.1% [71.2% to 83.0%]

Arm B: 72.8% [65.6% to 80.0%] diff: 20.6% [10.4% to 30.9%] HR = 0.45 [0.332 to 0.612] Median observation time 120 months

311 Arm B: 79.7% [73.9% to 85.6%] diff: 2.7% [-5.7% to 11.0%] HR = 0.813 [0.560 to 1.179] Median observation time 136 months

290

305

311

 Significantly superior 15-year PFS with CMT compared to EF-RT only  No significant difference in 15-year overall survival (OS) observed

Bröckelmann et al; EHA 2016